Drug Safety

, Volume 37, Issue 6, pp 421–431 | Cite as

Association of Statin Use with Sleep Disturbances: Data Mining of a Spontaneous Reporting Database and a Prescription Database

  • Mitsutaka TakadaEmail author
  • Mai Fujimoto
  • Kohei Yamazaki
  • Masashi Takamoto
  • Kouichi Hosomi
Original Research Article



Particular interest has been generated regarding the possible influence of statin use on sleep quality. However, no conclusive evidence exists that a particular statin is more likely to be associated with sleep disturbances versus others. It remains uncertain whether different statins produce different risks for sleep disturbance.


To examine the association between statin use and the risk of sleep disturbances, we conducted data mining using the US Food and Drug Administration Adverse Event Reporting System (FAERS) and a large organized database of prescriptions constructed by a database vendor (Japan Medical Information Research Institute, Inc. Japan).


Relevant reports in the FAERS were identified and analyzed. Data from the first quarter of 2004 through the end of 2013 were included in this study. The reporting odds ratio (ROR) was used to detect spontaneous report signals, calculated using the case/non-case method. For the ROR, a signal was detected if the lower limit of 95 % two-sided confidence interval (95 % CI) was >1. Additionally, signal detection using the IC was conducted using the IC025 metric, a lower limit of the 95 % CI of the IC, where a signal is detected if the IC025 value exceeds 0. In addition, symmetry analysis was used to identify the risk of insomnia after using statins over the period of January 2006 to August 2013.


In the analyses of the FAERS database, significant signals for sleep disturbances including disturbances in initiating and maintaining sleep, sleep disorders NEC, sleeping disorders due to a general medical condition, and parasomnias were found. In the prescription sequence symmetry analysis, a significant association between statin use and hypnotic drug use was found, with adjusted sequence ratios of 1.14 (1.03–1.26), 1.20 (1.11–1.29), and 1.18 (1.11–1.25) at intervals of 91, 182, and 365 days, respectively.


Multi-methodological approaches using different algorithms and databases strongly suggest that statin use is associated with an increased risk for sleep disturbances including insomnia.


Statin Sleep Disturbance Pravastatin Lovastatin Rosuvastatin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



We thank the Japan Medical Information Research Institute, Inc. for providing the database of prescriptions.

Conflict of interest statement

No sources of funding were used to assist in the preparation of this study. Mitsutaka Takada, Mai Fujimoto, Kohei Yamazaki, Masashi Takamoto, and Kouichi Hosomi have no conflicts of interest that are directly relevant to the content of this study.


  1. 1.
    Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1:CD004816.Google Scholar
  3. 3.
    Antons KA, Williams CD, Baker SK, Phillips PS. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med. 2006;119(5):400–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Ronaldson KJ, O’Shea JM, Boyd IW. Risk factors for rhabdomyolysis with simvastatin and atorvastatin. Drug Saf. 2006;29(11):1061–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Ardati A, Stolley P, Knapp DE, Wolfe SM, Lurie P. Statin-associated rhabdomyolysis. Pharmacoepidemiol Drug Saf. 2005;14(4):287.PubMedCrossRefGoogle Scholar
  6. 6.
    Eriksson M, Angelin B, Sjoberg S. Risk for fatal statin-induced rhabdomyolysis as a consequence of misinterpretation of ‘evidence-based medicine’. J Intern Med. 2005;257(3):313–4.PubMedCrossRefGoogle Scholar
  7. 7.
    Parale GP, Baheti NN, Kulkarni PM, Panchal NV. Effects of atorvastatin on higher functions. Eur J Clin Pharmacol. 2006;62(4):259–65.PubMedCrossRefGoogle Scholar
  8. 8.
    Tatley M, Savage R. Psychiatric adverse reactions with statins, fibrates and ezetimibe: implications for the use of lipid-lowering agents. Drug Saf. 2007;30(3):195–201.PubMedCrossRefGoogle Scholar
  9. 9.
    Suribhatla S, Dennis MS, Potter JF. A study of statin use in the prevention of cognitive impairment of vascular origin in the UK. J Neurol Sci. 2005;229–230:147–50.PubMedCrossRefGoogle Scholar
  10. 10.
    Golomb BA, Kane T, Dimsdale JE. Severe irritability associated with statin cholesterol-lowering drugs. QJM. 2004;97(4):229–35.PubMedCrossRefGoogle Scholar
  11. 11.
    MHRA public assessment report. Statins: updates to product safety information.
  12. 12.
    Ali AK. Pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibitor. Ther Clin Risk Manag. 2011;7:337–44.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385–96.PubMedCrossRefGoogle Scholar
  14. 14.
    Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2009;32(1):19–31.PubMedCrossRefGoogle Scholar
  15. 15.
    Rodriguez EM, Staffa JA, Graham DJ. The role of databases in drug postmarketing surveillance. Pharmacoepidemiol Drug Saf. 2001;10(5):407–10.PubMedCrossRefGoogle Scholar
  16. 16.
    Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969–2002: the importance of reporting suspected reactions. Arch Intern Med. 2005;165(12):1363–9.PubMedCrossRefGoogle Scholar
  17. 17.
    van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3–10.PubMedCrossRefGoogle Scholar
  18. 18.
    Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54(4):315–21.PubMedCrossRefGoogle Scholar
  19. 19.
    Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci. 2013;10(7):796–803.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Almenoff JS, Pattishall EN, Gibbs TG, DuMouchel W, Evans SJ, Yuen N. Novel statistical tools for monitoring the safety of marketed drugs. Clin Pharmacol Ther. 2007;82(2):157–66.PubMedCrossRefGoogle Scholar
  21. 21.
    Hallas J. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology. 1996;7(5):478–84.PubMedCrossRefGoogle Scholar
  22. 22.
    Tsiropoulos I, Andersen M, Hallas J. Adverse events with use of antiepileptic drugs: a prescription and event symmetry analysis. Pharmacoepidemiol Drug Saf. 2009;18(6):483–91.PubMedCrossRefGoogle Scholar
  23. 23.
    Hallas J, Gaist D, Bjerrum L. The waiting time distribution as a graphical approach to epidemiologic measures of drug utilization. Epidemiology. 1997;8(6):666–70.PubMedCrossRefGoogle Scholar
  24. 24.
    Morris JA, Gardner MJ. Calculating confidence intervals for relative risks (odds ratios) and standardised ratios and rates. Br Med J (Clin Res Ed). 1988;296(6632):1313–6.CrossRefGoogle Scholar
  25. 25.
    Tuccori M, Lapi F, Testi A, Coli D, Moretti U, Vannacci A, et al. Statin-associated psychiatric adverse events: a case/non-case evaluation of an Italian database of spontaneous adverse drug reaction reporting. Drug Saf. 2008;31(12):1115–23.PubMedCrossRefGoogle Scholar
  26. 26.
    Saheki A, Terasaki T, Tamai I, Tsuji A. In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm Res. 1994;11(2):305–11.PubMedCrossRefGoogle Scholar
  27. 27.
    Galatti L, Polimeni G, Salvo F, Romani M, Sessa A, Spina E. Short-term memory loss associated with rosuvastatin. Pharmacotherapy. 2006;26(8):1190–2.PubMedCrossRefGoogle Scholar
  28. 28.
    King DS, Wilburn AJ, Wofford MR, Harrell TK, Lindley BJ, Jones DW. Cognitive impairment associated with atorvastatin and simvastatin. Pharmacotherapy. 2003;23(12):1663–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Padala KP, Padala PR, Potter JF. Simvastatin-induced decline in cognition. Ann Pharmacother. 2006;40(10):1880–3.PubMedCrossRefGoogle Scholar
  30. 30.
    Roth T, Richardson GR, Sullivan JP, Lee RM, Merlotti L, Roehrs T. Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance. Clin Cardiol. 1992;15(6):426–32.PubMedCrossRefGoogle Scholar
  31. 31.
    Schaefer EJ. HMG-CoA reductase inhibitors for hypercholesterolemia. N Engl J Med. 1988;319:1222–3.CrossRefGoogle Scholar
  32. 32.
    Vgontzas AN, Kales A, Bixler EO, Manfredi RL, Tyson KL. Effects of lovastatin and pravastatin on sleep efficiency and sleep stages. Clin Pharmacol Ther. 1991;50(6):730–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Barth JD, Kruisbrink OA, Van Dijk AL. Inhibitors of hydroxymethylglutaryl coenzyme A reductase for treating hypercholesterolaemia. BMJ. 1990;301(6753):669.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Ehrenberg BL, Lamon-Fava S, Corbett KE, McNamara JR, Dallal GE, Schaefer EJ. Comparison of the effects of pravastatin and lovastatin on sleep disturbance in hypercholesterolemic subjects. Sleep. 1999;22(1):117–21.PubMedGoogle Scholar
  35. 35.
    Tuccori M, Montagnani S, Mantarro S, Capogrosso-Sansone A, Ruggiero E, Saporiti A, et al. Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management. CNS Drugs. 2014;28(3):249–72.Google Scholar
  36. 36.
    Engelberg H. Low serum cholesterol and suicide. Lancet. 1992;339(8795):727–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Liu X, Uchiyama M, Kim K, Okawa M, Shibui K, Kudo Y, et al. Sleep loss and daytime sleepiness in the general adult population of Japan. Psychiatry Res. 2000;93(1):1–11.PubMedCrossRefGoogle Scholar
  38. 38.
    Mellinger GD, Balter MB, Uhlenhuth EH. Insomnia and its treatment: prevalence and correlates. Arch Gen Psychiatry. 1985;42(3):225–32.PubMedCrossRefGoogle Scholar
  39. 39.
    Kuppermann M, Lubeck DP, Mazonson PD, Patrick DL, Stewart AL, Buesching DP, et al. Sleep problems and their correlates in a working population. J Gen Intern Med. 1995;10(1):25–32.PubMedCrossRefGoogle Scholar
  40. 40.
    Simon GE, VonKorff M. Prevalence, burden, and treatment of insomnia in primary care. Am J Psychiatry. 1997;154(10):1417–23.PubMedGoogle Scholar
  41. 41.
    Ancoli-Israel S, Roth T. Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. I. Sleep. 1999;22(Suppl. 2):S347–53.PubMedGoogle Scholar
  42. 42.
    Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders: an opportunity for prevention? JAMA. 1989;262(11):1479–84.PubMedCrossRefGoogle Scholar
  43. 43.
    Klink ME, Quan SF, Kaltenborn WT, Lebowitz MD. Risk factors associated with complaints of insomnia in a general adult population: influence of previous complaints of insomnia. Arch Intern Med. 1992;152(8):1634–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427–36.PubMedCrossRefGoogle Scholar
  45. 45.
    Motola D, Piccinni C, Biagi C, Raschi E, Marra A, Marchesini G, et al. Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database. Drug Saf. 2012;35(4):315–23.PubMedCrossRefGoogle Scholar
  46. 46.
    Sommet A, Grolleau S, Bagheri H, Lapeyre-Mestre M, Montastruc JL. Was the thrombotic risk of rofecoxib predictable from the French Pharmacovigilance Database before 30 September 2004? Eur J Clin Pharmacol. 2008;64(8):829–34.PubMedCrossRefGoogle Scholar
  47. 47.
    Lindquist M, Stahl M, Bate A, Edwards IR, Meyboom RH. A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database. Drug Saf. 2000;23(6):533–42.PubMedCrossRefGoogle Scholar
  48. 48.
    Tamura T, Sakaeda T, Kadoyama K, Okuno Y. Aspirin- and clopidogrel-associated bleeding complications: data mining of the public version of the FDA Adverse Event Reporting System, AERS. Int J Med Sci. 2012;9(6):441–6.PubMedCentralPubMedCrossRefGoogle Scholar
  49. 49.
    Murakami H, Sakaeda T, Kadoyama K, Okuno Y. Gender effects on statin-associated muscular adverse events: an analysis of the FDA AERS database. Pharmacol Pharmacy. 2013;4:340–6.CrossRefGoogle Scholar
  50. 50.
    Moore N, Kreft-Jais C, Haramburu F, Noblet C, Andrejak M, Ollagnier M, et al. Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database. Br J Clin Pharmacol. 1997;44(5):513–8.PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    Poluzzi E, Raschi E, Moretti U, De Ponti F. Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf. 2009;18(6):512–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Poluzzi E, Raschi E, Motola D, Moretti U, De Ponti F. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System. Drug Saf. 2010;33(4):303–14.PubMedCrossRefGoogle Scholar
  53. 53.
    Wahab IA, Pratt NL, Wiese MD, Kalisch LM, Roughead EE. The validity of sequence symmetry analysis (SSA) for adverse drug reaction signal detection. Pharmacoepidemiol Drug Saf. 2013;22(5):496–502.PubMedCrossRefGoogle Scholar
  54. 54.
    Lai EC, Yang YH, Lin SJ, Hsieh CY. Use of antiepileptic drugs and risk of hypothyroidism. Pharmacoepidemiol Drug Saf. 2013;22(10):1071–9.PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Mitsutaka Takada
    • 1
    Email author
  • Mai Fujimoto
    • 1
  • Kohei Yamazaki
    • 1
  • Masashi Takamoto
    • 1
  • Kouichi Hosomi
    • 1
  1. 1.Division of Clinical Drug Informatics, School of PharmacyKinki UniversityHigashi-osakaJapan

Personalised recommendations